{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P1Y", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "Division of Drug Information", "hasEmail": "mailto:druginfo@fda.hhs.gov"}, "description": "Qinlock (ripretinib) is an oral prescription tablet that acts as a kinase inhibitor, targeting enzymes like KIT and PDGFR alpha to help manage certain cancers. Manufactured by Deciphera Pharmaceuticals, LLC, it comes in 50 mg doses. This information was generated using AI and is provided for informational and research purposes only.", "distribution": [{"@type": "dcat:Distribution", "description": "\n        Access the FDA dataset for Ripretinib \u2014 ANDA 213973 submitted by Mylan Institutional LLC\n    ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213973", "mediaType": "text/html", "title": "Ripretinib"}], "identifier": "ANDA213973", "issued": "2016-09-16", "keyword": ["drug-information", "drug-manufacturers", "drug-safety", "medications", "pharmaceuticals"], "landingPage": "https://www.fda.gov/drugs", "license": "https://open.fda.gov/license", "modified": "2025-03-17", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Ripretinib"}